Pyrazolo[1,5-a]pyrimidine as a Prominent Framework for Tropomyosin Receptor Kinase (Trk) Inhibitors—Synthetic Strategies and SAR Insights
Open accessThe DOI matches its Crossref record; 79 of the 81 references it cites were found in a registry or an index.
Abstract
Tropomyosin receptor kinases (Trks) are transmembrane receptor tyrosine kinases named TrkA, TrkB, and TrkC and encoded by the NTRK1, NTRK2, and NTRK3 genes, respectively. These kinases have attracted significant attention and represent a promising therapeutic target for solid tumor treatment due to their vital role in cellular signaling pathways. First-generation TRK inhibitors, i.e., Larotrectinib sulfate and Entrectinib, received clinical approval in 2018 and 2019, respectively. However, the use of these inhibitors was significantly limited because of the development of resistance due to mutations. Fortunately, the second-generation Trk inhibitor Repotrectinib (TPX-0005) was approved by the FDA in November 2023, while Selitrectinib (Loxo-195) has provided an effective solution to this issue. Another macrocycle-based analog, along with many other TRK inhibitors, is currently in clinical trials. Two of the three marketed drugs for NTRK fusion cancers feature a pyrazolo[1,5-a] pyrimidine nucleus, prompting medicinal chemists to develop numerous novel pyrazolopyrimidine-based molecules to enhance clinical applications. This article focuses on a comprehensive review of chronological synthetic developments and the structure–activity relationships (SAR) of pyrazolo[1,5-a]pyrimidine derivatives as Trk inhibitors. This article will also provide comprehensive knowledge and future directions to the researchers working in the field of medicinal chemistry by facilitating the structural modification of pyrazolo [1,5-a]pyrimidine derivatives to synthesize more effective novel chemotherapeutics as TRK inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Schematic presentation of Trk receptors and their major signal transduction pathway [53,54].](https://figures.cochat.ai/paper-figures/d62543c727cc4739ad111a2b5b026089/pyrazolo-1-5-a-pyrimidine-as-a-prominent-framework-for-tropomyosin-receptor-figure-1.jpg)
![Figure 2 Development of NTRK fusion inhibitors consisting of a pyrazolo[1,5-a]pyrimidine moiety.](https://figures.cochat.ai/paper-figures/ef45e81708bc45d2b94fe8ebd4754ce3/pyrazolo-1-5-a-pyrimidine-as-a-prominent-framework-for-tropomyosin-receptor-figure-2.jpg)





















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sustained TrkB activation enhances survival and growth signaling, and Trk family receptors are established oncogenic drivers when aberrantly engaged [135,136,137].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [137]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurotrophins: Roles in Neuronal Development and Function
Huang, E. J., & Reichardt, L. F. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.677 · Cited by 4,394 · cited 9×
“and colleagues (2011) synthesized a new series of macrocyclic pyrazolo[1,5-a]pyrimidine derivatives and evaluated their activity using the TrkA Elisa enzyme assay.”
BackgroundInfluentialThe Conformational Plasticity of Protein Kinases
Huse, M., & Kuriyan, J. (2002) · Cell · doi:10.1016/s0092-8674(02)00741-9 · Cited by 1,752
NTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,485 · cited 1×
“…cancer, prostate cancer, large cell neuroendocrine tumors, pediatrics gliomas and astrocytomas, intrahepatic cholangiocarcinomas, gastrointestinal stromal tumors, gallbladder adenocarcinomas, pancreatic carcinomas, and many other cancers have been associated with oncogenic forms of NTRK [26–44].”
BackgroundKaplan, D. R., Martin-Zanca, D., & Parada, L. F. (1991) · Nature · doi:10.1038/350158a0 · Cited by 1,055 · cited 1×
“Mainly, nerve growth factor (NGF), neurotrophin-7, and neurotrophin-6 bind to TrkA, and activation of TrkA triggers various signaling pathways involved in cell survival, differentiation, and growth, particularly in neurons and neuroblastomas [5].”
BackgroundKlein, R., Nanduri, V., Jing, S., Lamballe, F., Tapley, P., Bryant, S., Cordon-Cardo, C., Jones, K. R., Reichardt, L. F., & Barbacid, M. (1991) · Cell · doi:10.1016/0092-8674(91)90628-c · Cited by 958 · cited 1×
“[6 ].”
A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences
Martin-Zanca, D., Hughes, S. H., & Barbacid, M. (1986) · Nature · doi:10.1038/319743a0 · Cited by 803
TRKing Down an Old Oncogene in a New Era of Targeted Therapy
Vaishnavi, A., Le, A. T., & Doebele, R. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0765 · Cited by 642 · cited 2×
“This leads to the activation of multiple downstream signal transduction pathways, such as PI3K-AKT and RAS-MAPK, and regulates the nervous system and neuronal cell cycle, proliferation, apoptosis, survival, and differentiation [9–13].”
BackgroundNTRK gene fusions as novel targets of cancer therapy across multiple tumour types
Amatu, A., Sartore-Bianchi, A., & Siena, S. (2016) · ESMO Open · doi:10.1136/esmoopen-2015-000023 · Cited by 601 · cited 1×
“However, in the pathophysiology of malignant cancer in humans, Trks can be seen to be active through NTRK gene fusions [13,14].”
BackgroundDrilon, A., Ou, S.-H. I., Cho, B. C., Kim, D.-W., Lee, J., Lin, J. J., Zhu, V. W., Ahn, M.-J., Camidge, D. R., Nguyen, J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0484 · Cited by 504 · cited 1×
“2023 while Selitrectinib (Loxo-195 macrocycle-based representative, along with many other inhibitors, is currently being in clinical trials [58–60].”
BackgroundOncogenes in solid human tumours
Pulciani, S., Santos, E., Lauver, A. V., Long, L. K., Aaronson, S. A., & Barbacid, M. (1982) · Nature · doi:10.1038/300539a0 · Cited by 478 · cited 1×
“Over 100 distinct NTRK fusion partners have been found in various malignancies to date, with the first NTRK fusion gene, TPM3-NTRK1, found in human colorectal carcinoma in 1982 [15,16].”
BackgroundPan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions
Hechtman, J. F., Benayed, R., Hyman, D. M., Drilon, A., Zehir, A., Frosina, D., Arcila, M. E., Dogan, S., Klimstra, D. S., Ladanyi, M., et al. (2017) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000911 · Cited by 468
Ross, J. S., Wang, K., Gay, L., Al-Rohil, R., Rand, J. V., Jones, D. M., Lee, H. J., Sheehan, C. E., Otto, G. A., Palmer, G., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0352 · Cited by 454
Drilon, A., Nagasubramanian, R., Blake, J. F., Ku, N., Tuch, B. B., Ebata, K., Smith, S., Lauriault, V., Kolakowski, G. R., Brandhuber, B. J., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0507 · Cited by 439
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
Amatu, A., Sartore-Bianchi, A., Bencardino, K., Pizzutilo, E. G., Tosi, F., & Siena, S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz383 · Cited by 309 · cited 1×
“It has been suggested that TRK proteins have been considered efficient “pan-cancer” targets for the treatment of various cancers harboring NTRK fusions [17,18].”
BackgroundFGFR1 and NTRK3 actionable alterations in “Wild-Type” gastrointestinal stromal tumors
Shi, E., Chmielecki, J., Tang, C.-M., Wang, K., Heinrich, M. C., Kang, G., Corless, C. L., Hong, D., Fero, K. E., Murphy, J. D., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1075-6 · Cited by 237
An insight on synthetic and medicinal aspects of pyrazolo[1,5-a]pyrimidine scaffold
Cherukupalli, S., Karpoormath, R., Chandrasekaran, B., Hampannavar, G. A., Thapliyal, N., & Palakollu, V. N. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.11.019 · Cited by 195 · cited 3×
“It has been engineered to exhibit speci fi c modes of action, including activities as central nervous system (CNS) agents, anti-bacterial agents, anti-in fl am-matory agents, anti-cancer agents, anti-fungal agents, antiviral agents, and ligands for estrogen receptors , [61,62].”
BackgroundInhibiting TRK Proteins in Clinical Cancer Therapy
Lange, A., & Lo, H.-W. (2018) · Cancers · doi:10.3390/cancers10040105 · Cited by 175
Medicinal attributes of pyrazolo[3,4-d]pyrimidines: A review
Chauhan, M., & Kumar, R. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.07.027 · Cited by 168 · cited 3×
“…anti-bacterial agents, anti-in fl am-matory agents, anti-cancer agents, anti-fungal agents, antiviral agents, and ligands for estrogen receptors [61,62]. system (CNS) agents, anti-bacterial agents, anti-inflammatory agents, anti-cancer agents, anti-fungal agents, antiviral agents, and ligands for…”
BackgroundThe nerve growth factor and its receptors in airway inflammatory diseases
Freund-Michel, V., & Frossard, N. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.07.003 · Cited by 158
Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers
Jiang, T., Wang, G., Liu, Y., Feng, L., Wang, M., Liu, J., Chen, Y., & Ouyang, L. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.05.004 · Cited by 157 · cited 1×
“The overall sequence homology of the kinase domains of TrkA, TrkB, and TrkC ranges from 71.9% to 78.3%, with TrkB and TrkC exhibiting the highest degree of similarity [3,4].”
BackgroundInfluentialdi Mola, F. F. (2000) · Gut · doi:10.1136/gut.46.5.670 · Cited by 152
NGF/TrkA Signaling as a Therapeutic Target for Pain
Hirose, M., Kuroda, Y., & Murata, E. (2016) · Pain Practice · doi:10.1111/papr.12342 · Cited by 140 · cited 1×
“…involved in cancer metastasis but also in various other diseases such as asthma [45], interstitial cystitis [46], inflammatory diseases such as ulcerative colitis and Crohn’s disease [47], atopic dermatitis [48], eczema and psoriasis [49], pain [50], Alzheimer’s disease [51], and inflammation [52].”
BackgroundIncreased nerve growth factor and its receptors in atopic dermatitis: an immunohistochemical study
Dou, Y., Hagströmer, L., Emtestam, L., & Johansson, O. (2006) · Archives of Dermatological Research · doi:10.1007/s00403-006-0657-1 · Cited by 123 · cited 1×
“…involved in cancer metastasis but also in various other diseases such as asthma [45], interstitial cystitis [46], inflammatory diseases such as ulcerative colitis and Crohn’s disease [47], atopic dermatitis [48], eczema and psoriasis [49], pain [50], Alzheimer’s disease [51], and inflammation [52].”
BackgroundDionne, C. A., Camoratto, A. M., Jani, J. P., Emerson, E., Neff, N. T., Vaught, J. L., Murakata, C., Djakiew, D., Lamb, J., Bova, G. S., et al. (1998) · PubMed · Cited by 118
Reuther, G. W., Lambert, Q. T., Caligiuri, M. A., & Der, C. J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.23.8655-8666.2000 · Cited by 118
Nerve Growth Factor Downregulates Inflammatory Response in Human Monocytes through TrkA
Prencipe, G., Minnone, G., Strippoli, R., De Pasquale, L., Petrini, S., Caiello, I., Manni, L., De Benedetti, F., & Bracci-Laudiero, L. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1300825 · Cited by 117 · cited 1×
“…involved in cancer metastasis but also in various other diseases such as asthma [45], interstitial cystitis [46], inflammatory diseases such as ulcerative colitis and Crohn’s disease [47], atopic dermatitis [48], eczema and psoriasis [49], pain [50], Alzheimer’s disease [51], and inflammation [52].”
BackgroundDang, C., Zhang, Y., Ma, Q., & Shimahara, Y. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04074.x · Cited by 117
Fraley, M. E., Hoffman, W. F., Rubino, R. S., Hungate, R. W., Tebben, A. J., Rutledge, R. Z., McFall, R. C., Huckle, W. R., Kendall, R. L., Coll, K. E., et al. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00525-5 · Cited by 115 · cited 2×
“…4-phenylpyrazolamine derivative with phenyl acrylaldehyde in the presence of acetic acid and Fraley et al. have synthesized the desired novel PP by treating a 4-phenylpyrazola-mine derivative with phenyl acrylaldehyde in the presence of acetic acid and ethanol as a solvent (route a) [66]. a) [66].”
BackgroundIvachtchenko, A. V., Golovina, E. S., Кадиева, M. Г., Kysil, V. M., Mitkin, O. D., Tkachenko, S. E., & Okun, I. M. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201079g · Cited by 111
Huang, X. L., Khan, M. I., Wang, J., Ali, R., Ali, S. W., Zahra, Q. U. A., Kazmi, A., Lolai, A., Huang, Y., Hussain, A., et al. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.03.075 · Cited by 111
Forsythe, A., Zhang, W., Strauss, U. P., Fellous, M., Korei, M., & Keating, K. N. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920975613 · Cited by 101 · cited 1×
“A broad spectrum of cancer types, i.e., NTRK fusions, are found across a wide variety of cancer types [19,20].”
BackgroundRaychaudhuri, S. P., Sanyal, M., Weltman, H., & Kundu‐Raychaudhuri, S. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2003.12602.x · Cited by 96 · cited 1×
“…involved in cancer metastasis but also in various other diseases such as asthma [45], interstitial cystitis [46], inflammatory diseases such as ulcerative colitis and Crohn’s disease [47], atopic dermatitis [48], eczema and psoriasis [49], pain [50], Alzheimer’s disease [51], and inflammation [52].”
BackgroundA function–structure model for NGF‐activated TRK
Cunningham, M. E., & Greene, L. A. (1998) · The EMBO Journal · doi:10.1093/emboj/17.24.7282 · Cited by 94
Yan, W., Lakkaniga, N. R., Carlomagno, F., Santoro, M., McDonald, N. Q., Lv, F., Naresh, G., Frett, B., & Li, H. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01092 · Cited by 93
Histology-agnostic drug development — considering issues beyond the tissue
Pestana, R. C., Sen, S., Hobbs, B. P., & Hong, D. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0384-0 · Cited by 87 · cited 1×
“It has been suggested that TRK proteins have been considered efficient “pan-cancer” targets for the treatment of various cancers harboring NTRK fusions [17,18].”
BackgroundDECREASE IN BLADDER OVERACTIVITY WITH REN1820 IN RATS WITH CYCLOPHOSPHAMIDE INDUCED CYSTITIS
Hu, V. Y., Zvara, P., Dattilio, A., Redman, T. L., Allen, S. J., Dawbarn, D., Stroemer, R. P., & Vizzard, M. A. (2005) · The Journal of Urology · doi:10.1097/01.ju.0000155170.15023.e5 · Cited by 85 · cited 1×
“NTRK fusion is not only involved in cancer metastasis but also in various other diseases such as asthma [45], interstitial cystitis [46], inflammatory diseases such as ulcerative colitis and Crohn’s disease [47], atopic dermatitis [48], eczema and psoriasis [49], pain [50], Alzheimer’s disease…”
BackgroundMarchetti, A., Felicioni, L., Pelosi, G., Del Grammastro, M., Fumagalli, C., Sciarrotta, M., Malatesta, S., Chella, A., Barassi, F., Mucilli, F., et al. (2008) · Human Mutation · doi:10.1002/humu.20707 · Cited by 79
Synthesis and Anti‐tumor Activities of Novel Pyrazolo[1,5‐a]pyrimidines
Li, J., Zhao, Y. F., Zhao, X. L., Yuan, X. Y., & Gong, P. (2006) · Archiv der Pharmazie · doi:10.1002/ardp.200600098 · Cited by 72 · cited 1×
“…in the presence of acetone as a solvent under refluxed Li and colleagues synthesized PP by performing the reaction between 5-aminopyrazole and ethyl 4-chloroacetoacetate in the presence of acetone as a solvent under re fl uxed conditions (route d) [69]. conditions (route d) [69].”
MethodNTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors
Somwar, R., Hofmann, N. E., Smith, B. D., Odintsov, I., Vojnic, M., Linkov, I., Tam, A., Khodos, I., Mattar, M. S., de Stanchina, E., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01508-w · Cited by 70 · cited 1×
“A driver mutation is a genetic alteration that provides a selective growth advantage to cancer cells, contributing to their proliferation and survival [21,22].”
BackgroundTropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer
Laetsch, T. W., & Hong, D. S. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0465 · Cited by 69 · cited 2×
“Switzerland) are first-generation Trk inhibitors on the market (Figure 2) [55–57]. drugs were found to have massive clinical findings against Trk; however, the emergence of drug resistance in clinics restricted their extensive use.”
BackgroundPyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2
Paruch, K., Dwyer, M. P., Alvarez, C., Brown, C. L., Chan, T., Doll, R. J., Keertikar, K. M., Knutson, C. E., McKittrick, B. A., Rivera, J., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.09.017 · Cited by 68 · cited 1×
“…et al. invented the one-pot synthesis of new PP analogs by reacting 1 H -pyrazol-5-amine derivatives with methyl-3-oxobutanoate, phosphorus oxychloride and N, Paruch et al. invented the one-pot synthesis of new PP analogs by reacting 1 H - dimethylaniline under inert conditions (route e) [70].”
MethodIsmail, N. S. M., Ali, G., Ibrahim, D. A., & Elmetwally, A. M. (2016) · Future Journal of Pharmaceutical Sciences · doi:10.1016/j.fjps.2016.08.004 · Cited by 60
Savaskan, E., Müller-Spahn, F., Olivieri, G., Bruttel, S., Otten, U., Rosenberg, C., Hulette, C., & Hock, C. (2000) · European Neurology · doi:10.1159/000008229 · Cited by 58 · cited 1×
“…involved in cancer metastasis but also in various other diseases such as asthma [45], interstitial cystitis [46], inflammatory diseases such as ulcerative colitis and Crohn’s disease [47], atopic dermatitis [48], eczema and psoriasis [49], pain [50], Alzheimer’s disease [51], and inflammation [52].”
BackgroundLee, Y., Chen, J.-Y., Huang, C.-J., Chen, H.-S., Yang, A., & Hang, J. (2020) · Endocrine Pathology · doi:10.1007/s12022-020-09648-9 · Cited by 54
Entrectinib in TRK and ROS1 Fusion-Positive Metastatic Pancreatic Cancer
Pishvaian, M. J., Garrido‐Laguna, I., Liu, S. V., Multani, P. S., Chow‐Maneval, E., & Rolfo, C. D. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00039 · Cited by 53 · cited 1×
“…cancer, prostate cancer, large cell neuroendocrine tumors, pediatrics gliomas and astrocytomas, intrahepatic cholangiocarcinomas, gastrointestinal stromal tumors, gallbladder adenocarcinomas, pancreatic carcinomas, and many other cancers have been associated with oncogenic forms of NTRK [26–44].”
BackgroundTropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 –Part I
Bailey, J. J., Schirrmacher, R., Farrell, K. B., & Bernard‐Gauthier, V. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1297796 · Cited by 51 · cited 1×
“2023 while Selitrectinib (Loxo-195 macrocycle-based representative, along with many other inhibitors, is currently being in clinical trials [58–60].”
BackgroundDiscovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer
Liu, Z., Yu, P., Dong, L., Wang, W., Duan, S., Wang, B., Gong, X., Liang, Y. S., Wang, H., & Tian, J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00712 · Cited by 51 · cited 2×
“The lipophilicity of compound 37 was increased, leading to enhanced metabolic stability and a favorable in vivo pro fi le with reduced toxicity [93 16 of 23 The con fi guration and position of the methyl group at R 2 notably in fl uenced its activity. against ALK with an IC 50 value of 350 nM, yet…”
Background7-Aminopyrazolo[1,5- a ]pyrimidines as Potent Multitargeted Receptor Tyrosine Kinase Inhibitors
Frey, R. R., Curtin, M. L., Albert, D. H., Glaser, K. B., Pease, L. J., Soni, N. B., Bouska, J. J., Reuter, D. R., Stewart, K. D., Marcotte, P. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701397k · Cited by 50
Recent synthetic methodologies for pyrazolo[1,5-a]pyrimidine
Salem, M. A., Helal, M. H., Gouda, M. A., El‐Gawad, H. H. A., Shehab, M. A. M., & El-Khalafawy, A. (2019) · Synthetic Communications · doi:10.1080/00397911.2019.1604967 · Cited by 48 · cited 2×
“PP can be readily synthesized by using Due to its prevalence in NTRK fusion inhibitors, we have also covered the synthesis and biological action of PP among the four isoforms. enamines, β -diketones, and α , β -unsaturated ketones reacted with 1 H -pyrazole-5-amine [65].”
BackgroundKosugi, T., Mitchell, D. R., Fujino, A., Imai, M., Kambe, M., Kobayashi, S., Makino, H., Matsueda, Y., Oue, Y., Komatsu, K., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300411k · Cited by 46
TrkB transmembrane domain: bridging structural understanding with therapeutic strategy
Enkavi, G., Girych, M., Moliner, R., Vattulainen, I., & Castrén, E. (2024) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2024.02.001 · Cited by 44
Tropomyosin-receptor-kinases signaling in the nervous system.
Stoleru, B., Popescu, A. M., Tache, D. E., Neamţu, O. M., Emami, G., Tătăranu, L. G., Buteică, S. A., Dricu, A., & Purcaru, Ş. O. (2013) · Europe PMC (PubMed Central) · Cited by 43
Discovery of pyrazolo[1,5-a]pyrimidine-based Pim inhibitors: A template-based approach
Dwyer, M. P., Keertikar, K. M., Paruch, K., Alvarez, C., Labroli, M. A., Poker, C., Fischmann, T. O., Mayer‐Ezell, R., Bond, R. W., Wang, Y., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.08.110 · Cited by 42
Xu, X., Song, L., Li, Y., Guo, J., Huang, S., Du, S., Li, W., Cao, R., & Cui, S. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04609-2 · Cited by 41 · cited 1×
“[7 ,8].”
Ranzi, V., Meakin, S. O., Miranda, C., Mondellini, P., Pierotti, M. A., & Greco, A. (2003) · Endocrinology · doi:10.1210/en.2002-221002 · Cited by 40
Xiang, S., & Lu, X. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.11.010 · Cited by 37 · cited 1×
“This makes Trk inhibitors promising options for patients with advanced or metastatic cancers that harbor these specific genetic alterations [24,25].”
BackgroundResearch Advances in the Role of the Tropomyosin Family in Cancer
Meng, Y., Huang, K., Shi, M., Huo, Y., Han, L., Liu, B., & Li, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713295 · Cited by 34
NTRK Therapy among Different Types of Cancers, Review and Future Perspectives
Theik, N. W. Y., Muminovic, M., Alvarez-Pinzon, A. M., Shoreibah, A., Hussein, A. M., & Raez, L. E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042366 · Cited by 34 · cited 1×
“A driver mutation is a genetic alteration that provides a selective growth advantage to cancer cells, contributing to their proliferation and survival [21,22].”
BackgroundBiological activity of the thyroid TRK-T3 oncogene requires signalling through Shc
Roccato, E., Miranda, C., Ranzi, V., Gishizki, M., Pierotti, M. A., & Greco, A. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600544 · Cited by 30
Compton, D. R., Carlson, K. E., & Katzenellenbogen, J. A. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.08.046 · Cited by 30
Regua, A. T., Aguayo, N. R., Jalboush, S. A., Doheny, D. L., Manore, S. G., Zhu, D., Wong, G. L., Arrigo, A., Wagner, C. J., Yu, Y., et al. (2021) · Cancers · doi:10.3390/cancers13102340 · Cited by 26
New pyrazolo[1,5a]pyrimidines as orally active inhibitors of Lck
Gommermann, N., Buehlmayer, P., von Matt, A., Breitenstein, W., Masuya, K., Pirard, B., Furet, P., Cowan‐Jacob, S. W., & Weckbecker, G. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.04.112 · Cited by 25
Iannantuono, G. M., Riondino, S., Sganga, S., Rosenfeld, R., Guerriero, S., Carlucci, M., Capotondi, B., Torino, F., & Roselli, M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12111819 · Cited by 25 · cited 1×
“Trk inhibitors specifically target the abnormal TRK fusion proteins, inhibiting their function and thereby inhibiting growth [23].”
BackgroundRoutes to Pyrazolo[3,4‐e][1,4]thiazepine, Pyrazolo[1,5‐a]pyrimidine and Pyrazole Derivatives
Elmaaty, T. A., & El‐Taweel, F. M. (2003) · Journal of the Chinese Chemical Society · doi:10.1002/jccs.200300063 · Cited by 23
Pyrazolo[1,5-a]pyrimidine based Trk inhibitors: Design, synthesis, biological activity evaluation
Zhang, Y. J., Liu, Y., Zhou, Y., Zhang, Q., Han, T., Tang, C., & Fan, W. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127712 · Cited by 23 · cited 1×
“Additionally, methyl substitution at the benzylic amine notably increased inhibitory activity structural modi fi cations [92].”
BackgroundGong, Y., Wu, F., Wang, M., Xu, H.-C., Zhuo, L., Yang, G., & Huang, W. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114654 · Cited by 22 · cited 1×
“…tumor growth inhibition rates of 97% at 30 mg/kg/dose and 73% at 100 mg/kg/dose in xenograft mouse models for both TrkAWT and TrkAG667C mutations [94]. incorporation enhanced interactions with Asn655, while a pyridine ring supported hydrophobic interactions, contributing to overall potency.”
BackgroundAl-Qadhi, M. A., Allam, H. A., Fahim, S. H., Yahya, T. A. A., & Ragab, F. A. F. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115918 · Cited by 20
TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions
Roviello, G., D’Angelo, A., Sciortino, M., Mini, E., Nobili, S., Logu, F. D., & Massi, D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103011 · Cited by 19 · cited 2×
“Switzerland) are first-generation Trk inhibitors on the market (Figure 2) [55–57]. drugs were found to have massive clinical findings against Trk; however, the emergence of drug resistance in clinics restricted their extensive use.”
BackgroundLozano-Ureña, A., & Frade, J. M. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1271820 · Cited by 19 · cited 1×
“This leads to the activation of multiple downstream signal transduction pathways, such as PI3K-AKT and RAS-MAPK, and regulates the nervous system and neuronal cell cycle, proliferation, apoptosis, survival, and differentiation [9–13].”
BackgroundDevi, A. S., Kaping, S., & Vishwakarma, J. N. (2015) · Molecular Diversity · doi:10.1007/s11030-015-9606-2 · Cited by 18
Synthesis and antitumor activity of novel pyrazolo[1,5-a]pyrimidine derivatives
El‐Enany, M. M., Kamel, M. M., Khalil, O. M., & El‐Nassan, H. B. (2011) · European Journal of Chemistry · doi:10.5155/eurjchem.2.3.331-336.319 · Cited by 18
Kang, M., Chong, K. Y., Hartwich, T. M. P., Bi, F., Witham, A. K., Patrick, D. A., Morrisson, M. J., Cady, S. L., Cerchia, A. P., Kelk, D. A., et al. (2020) · Oncogenesis · doi:10.1038/s41389-020-0243-y · Cited by 18
Design, synthesis and biological evaluation of macrocyclic derivatives as TRK inhibitors
Li, P. S., Cai, S., Zhao, T., Xu, L., Guan, D., Li, J., Zhou, J., & Zhang, H. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128409 · Cited by 15 · cited 1×
“…variations of the sulfonamide group, could enhance potency and selectivity against TRKG595R while maintaining overall kinase inhibition [91]. cyclic groups such as cyclopropane and tetrahydrofuran could lead to compounds with improved pharmacokinetic properties and selectivity les…”
BackgroundWu, S., Liu, Y., Shi, X., Zhou, W., & Zeng, X. (2023) · Digestive and Liver Disease · doi:10.1016/j.dld.2023.04.019 · Cited by 13
Kozaki, R., Yoshizawa, T., Tsukamoto, K., Kato, H., & Kawabata, K. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-2954a · Cited by 12 · cited 1×
“Transmembrane receptor proteins, or TRKs, are composed of three domains: an intracellular domain with activity, a transmembrane domain, and an extracellular ligand-binding domain [2].”
BackgroundFan, Y., Zhang, Y. J., Liu, Y., Jiang, H., Zhou, Y., Tang, C., & Fan, W. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128646 · Cited by 10
Metwally, N. H., Deeb, E. A., & Hasani, I. W. (2024) · BMC Chemistry · doi:10.1186/s13065-024-01166-7 · Cited by 9 · cited 2×
“Recently, Metwally et al. (2024) developed a new series of molecules and evaluated their e ffi cacy against MCF7, HepG2, and HCT116 cell lines (see Figure 23).”
BackgroundTRK inhibitors: managing on-target toxicities
Lim, J. S. J., & Tan, D. S. P. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.010 · Cited by 7 · cited 1×
“This makes Trk inhibitors promising options for patients with advanced or metastatic cancers that harbor these specific genetic alterations [24,25].”
BackgroundSpliceosomal Targeting in Acute Myeloid Leukemia Cells with ETV6-NTRK3 Fusion.
Chen, S., Schneider, B., Nagel, S., Geffers, R., Kaufmann, M., Quentmeier, H., Drexler, H. G., & MacLeod, R. A. F. (2009) · Blood · doi:10.1182/blood.v114.22.5042.5042 · Cited by 5
Research works printed but not linked: 4
- Ando, H., Ukena, K., and Nagata, S. (2021). Neurotrophin-3. Handbook of Hormones (Second Edition), Academic Press.
- Mansour, H.M., Khattab, M.M., and El-khatib, A.S. (2023). Receptor Tyrosine Kinases (RTKs): From Biology to Pathophysiology. Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders, Academic Press.
- Mansour, H.M., Khattab, M.M., and El-khatib, A.S. (2023). Chapter 3—Roles of Trk Receptors, Tyrosine Kinase Receptors for Neurotrophins, in the Developing CNS. Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders, Academic Press.
- Rashad, 2014, The Chemistry of Pyrazolopyrimidines and Their Applications, Org. Chem. Ind. J., 10, 224
Cited by
Iorkula, T. H., Osayawe, O. J.-K., Odogwu, D. A., Ganiyu, L. O., Faderin, E., Awoyemi, R. F., Akodu, B. O., Ifijen, I. H., Aworinde, O. R., Agyemang, P., et al. (2025) · RSC Advances · doi:10.1039/d4ra07556k · Cited by 75
Ahmed, A. A., Mekky, A. E. M., & Sanad, S. M. H. (2024) · Synthetic Communications · doi:10.1080/00397911.2024.2428653 · Cited by 15
Elgiushy, H. R., Soliman, M. E., El‐Khouly, M. E., Abouzid, K. A. M., & Hammad, S. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108792 · Cited by 8
Nasehi, P., Omidkhah, N., & Ghodsi, R. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108950 · Cited by 6
Efremov, A. N., Mitrofanov, A. Y., & Beletskaya, I. P. (2025) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5c01957 · Cited by 3
Metadata
- Authors
- Mahajan, A. T., Shivani, Datusalia, A. K., Coluccini, C., Coghi, P., & Chaudhary, S.
- Affiliations
- National Institute of Pharmaceutical Education and Research (IN)
- China Medical University (TW)
- Macau University of Science and Technology (MO)
- Corresponding author
- Coluccini, Carmine
- Coghi, Paolo
- Chaudhary, Sandeep
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2024-07-29
- Volume
- 29
- Issue
- 15
- Pages
- 3560
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC11314189
- OpenAlex
- W4401080166
- Cited by
- 12
- References
- 81
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 1
- FWCI
- 0.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- NIPER-Raebareli (CRG/2019/005102, MOST 110-2113-M-039-001, MOST 111-2221-E-039-009, 0005-2023-RIA1)
- Science and Engineering Research Board (SERB) (CRG/2019/005102, MOST 110-2113-M-039-001, MOST 111-2221-E-039-009, 0005-2023-RIA1)
- Ministry of Science and Technology in Taiwan (CRG/2019/005102, MOST 110-2113-M-039-001, MOST 111-2221-E-039-009, 0005-2023-RIA1)
- Macao Science and Technology University (CRG/2019/005102, MOST 110-2113-M-039-001, MOST 111-2221-E-039-009, 0005-2023-RIA1)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and Characterization of Heterocyclic Compounds
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- Trk receptors, TRK inhibitors, pyrazolo[1,5-a]pyrimidines, structure-activity relationship, larotrectinib, entrectinib, repotrectinib, resistance mutations, synthetic strategies, tyrosine kinase inhibitors
- MeSH terms
- Antineoplastic Agents, Humans, Neoplasms, Pyrazoles, Pyrimidines, Structure-Activity Relationship, Receptor, trkC, Receptor, trkB, Receptor, trkA, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.